The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate

• Michael Bobardt,

  Roles Methodology

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Joseph Kuo,

  Roles Formal analysis

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Udayan Chatterji,

  Roles Methodology

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Sumit Chanda,

  Roles Resources

  Affiliation Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States of America

  ⨯
• Susan J. Little,

  Roles Resources

  Affiliation Department of Medicine, University of California, San Diego, California, United States of America

  ⨯
• Norbert Wiedemann,

  Roles Conceptualization, Resources, Writing – review & editing

  Affiliation Debiopharm International S.A., Lausanne, Switzerland

  ⨯
• Gregoire Vuagniaux,

  Roles Conceptualization, Funding acquisition, Resources, Writing – review & editing

  Affiliation Debiopharm International S.A., Lausanne, Switzerland

  ⨯
• Philippe A. Gallay

  Roles Conceptualization, Data curation, Formal analysis, Investigation, Project administration, Supervision, Validation, Visualization, Writing – original draft

  * E-mail: gallay@scripps.edu

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  http://orcid.org/0000-0002-6151-4764

  ⨯